- Home
- BBD vs ILMN Comparison
BBD vs ILMN Comparison
Compare BBD & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBD
- ILMN
- Stock Information
- Founded
- BBD 1943
- ILMN 1998
- Country
- BBD Brazil
- ILMN United States
- Employees
- BBD N/A
- ILMN N/A
- Industry
- BBD Major Banks
- ILMN Medical Specialities
- Sector
- BBD Finance
- ILMN Health Care
- Exchange
- BBD Nasdaq
- ILMN Nasdaq
- Market Cap
- BBD 30.6B
- ILMN 15.3B
- IPO Year
- BBD N/A
- ILMN 2000
- Fundamental
- Price
- BBD $3.41
- ILMN $100.00
- Analyst Decision
- BBD Strong Buy
- ILMN Hold
- Analyst Count
- BBD 4
- ILMN 14
- Target Price
- BBD $2.55
- ILMN $120.29
- AVG Volume (30 Days)
- BBD 63.7M
- ILMN 1.6M
- Earning Date
- BBD 10-29-2025
- ILMN 10-30-2025
- Dividend Yield
- BBD 4.93%
- ILMN N/A
- EPS Growth
- BBD 58.81
- ILMN N/A
- EPS
- BBD 0.36
- ILMN 7.91
- Revenue
- BBD $16,114,445,927.00
- ILMN $4,284,000,000.00
- Revenue This Year
- BBD $77.46
- ILMN N/A
- Revenue Next Year
- BBD $7.42
- ILMN $2.74
- P/E Ratio
- BBD $8.68
- ILMN $12.66
- Revenue Growth
- BBD 27.09
- ILMN N/A
- 52 Week Low
- BBD $1.84
- ILMN $68.70
- 52 Week High
- BBD $3.41
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- BBD 63.08
- ILMN 54.48
- Support Level
- BBD $3.28
- ILMN $95.85
- Resistance Level
- BBD $3.39
- ILMN $101.93
- Average True Range (ATR)
- BBD 0.07
- ILMN 3.62
- MACD
- BBD 0.01
- ILMN 0.59
- Stochastic Oscillator
- BBD 96.05
- ILMN 83.92
About BBD Banco Bradesco Sa
Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation—a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.